


PHARMACEUTICAL 2021



Cogent Biosciences Inc. Rank 136 of 409





PHARMACEUTICAL 2021



Cogent Biosciences Inc. Rank 136 of 409

The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 185% points. The greatest weakness of Cogent Biosciences Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -34%, being 321% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	244,912
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,094
Liabilities, Non-Current	3,155
Other Assets	5,870
Other Compr. Net Income	0
Other Expenses	46,910
Other Liabilities	0
Other Net Income	7,391
Property and Equipment	134
Research and Development	25,738
Revenues	7,871
Selling, General and Administrative Expense	17,422

Output Variable	Value in 1000 USD
Assets	250,916
Liabilities	16,249
Expenses	90,070
Stockholders Equity	234,667
Net Income	-74,808
Comprehensive Net Income	-74,808
Economic Capital Ratio	-34%